Pharmaceutical Registration in Uruguay: the MSP to AViSU Transition and What It Means for Exporters

Three and a half million people. Most exporters look at that number, decide Uruguay is not worth the paperwork, and move on to Brazil.

I would push back on that, and not out of sentiment. Uruguay is a high-income country with a health system that works, procurement that is unusually transparent by regional standards, and payers who pay. The effort-to-return ratio compares well against markets ten times the size where you spend two years chasing receivables. It is also a founding Mercosur member, which means an Uruguayan registration is a credential you can carry into conversations in Buenos Aires and São Paulo.

There is also something happening here right now that makes the timing interesting. Uruguay is in the middle of moving medicines regulation out of a ministry department and into a proper standalone agency. If you are planning entry over the next year or two, that transition is the thing to understand — and it means most of the guidance floating around online is already describing a system that is being replaced.

Medicines regulation in Uruguay has historically sat with the Ministry of Public Health (Ministerio de Salud Pública, MSP), through its medicines evaluation and sanitary control functions, which handle registration, GMP oversight and pharmacovigilance.

That is changing. Under the national Budget Law for 2025–2029 (Ley N° 20.446), Uruguay has created the Agencia de Vigilancia Sanitaria del Uruguay (AViSU) — a non-state public entity with technical, administrative and financial autonomy, linked to and supervised by the Ministry of Public Health. The Pan American Health Organization publicly welcomed the approval in October 2025.

AViSU's remit covers medicines, vaccines, medical devices and cosmetics — authorising, controlling and monitoring both pre- and post-market phases for quality, safety, efficacy and traceability — and it will also authorise and oversee clinical trials, including protocols, sites and investigators. The agency is expected to become operational during 2026 as part of the Budget Law's implementation.

Uruguay already participates as an observer at the Pan American Health Organization's Regional Reference Regulatory Authorities meetings. The clear intent behind AViSU is to give Uruguay an agency comparable in structure to ANMAT in Argentina or ANVISA in Brazil.

A locally established entity has to hold the registration and answer to the authority. No registering from abroad.

Here the small-market logic works against people. Because Uruguay looks minor on a sales forecast, exporters hand the registration to whoever will take it — usually the first distributor who offers — on the reasoning that the country is too small to justify setting anything up properly.

I understand the reasoning and I think it is usually wrong. What Uruguay is worth to you is often not the Uruguayan revenue. It is a Mercosur registration, a clean regulatory track record in a well-run market, and a reference you can point to when Argentina or Brazil ask who else has approved you. That is a portfolio asset. Giving control of it away because the first-year sales line looked unimpressive is the kind of decision that reads very differently three years later.

Judge the holder question on what the registration is worth strategically, not on what it will invoice.

Uruguay expects a full technical dossier supporting quality, safety and efficacy, together with documentation establishing the standing of the product and the manufacturing site. In broad terms:

• Certificate of Pharmaceutical Product (CoPP) in WHO format, legalised for use in Uruguay.
• GMP certificate for the manufacturing site. Mercosur has its own Good Manufacturing and Distribution Practice framework, and the recognition status of your site's certification within that framework is worth establishing early.
• Manufacturing licence and current inspection standing.
• Finished product specification and validated method of analysis.
• Batch Certificate of Analysis, traceable to batch number.
• Stability data supporting the labelled shelf life and storage condition for the applicable climatic zone. Uruguay's temperate climate differs from most of the region — data assembled for tropical markets is not automatically the most appropriate evidence here, and vice versa.
• Bioequivalence data where required for the category.
• Spanish labelling, packaging artwork and patient information.
• Legalised power of attorney appointing the local holder.

Because the institutional framework is actively changing, confirm the current required set, the correct filing route and the responsible office before compiling anything. This is not a market to plan from a two-year-old guidance document.

Three factors can reduce the burden of entering Uruguay.

Mercosur alignment. Uruguay is a founding Mercosur member, and the bloc maintains harmonised technical work including Good Manufacturing and Distribution Practice standards. Where your site and dossier already satisfy Mercosur-aligned expectations — typically through an Argentine or Brazilian filing — that work is not starting from zero in Uruguay.

Regional reference authorities. The Pan American Health Organization designates eight Regional Reference Regulatory Authorities: ANMAT (Argentina), ANVISA (Brazil), Health Canada, ISP (Chile), INVIMA (Colombia), CECMED (Cuba), US FDA and COFEPRIS (Mexico). Two of those are Uruguay's immediate Mercosur neighbours. An existing ANMAT or ANVISA approval is therefore unusually well-placed leverage for a Uruguayan filing.

The AViSU transition itself. A stated purpose of the new agency is more agile processes and alignment with international standards. Agencies in transition can be slower in the short term while procedures bed in, then faster once established. Both effects are real; build some tolerance into your timeline rather than assuming either.

Reliance is applied at the authority's discretion and varies by product category. Confirm what is actually available for your product before relying on it.

Any specific timeline quoted for Uruguay at present should be treated with caution, because responsibilities are moving between institutions. What can be said with confidence is structural rather than numerical.

Elapsed time is driven principally by deficiency cycles, not by the published review period. A complete, correctly formatted dossier filed once will always outperform a partial one filed early — and during an institutional transition, the cost of a query cycle is likely to be higher than normal, because clarifications may take longer to resolve while procedures are being established.

Registrations are granted for a fixed term and require renewal. If you are entering during the transition, confirm explicitly which body will handle your renewal and under what procedure, rather than assuming continuity.

Practical advice for the transition period: get confirmations in writing, keep a documented record of what was submitted and when, and do not rely on informal guidance that predates the new agency.

Documents issued abroad require authentication before Uruguayan authorities will accept them.

Uruguay is a party to the Hague Apostille Convention, as is India. Where both countries are parties, public documents can generally be authenticated by apostille rather than through full consular legalisation — materially faster and cheaper. Confirm the current position before arranging consular appointments.

The recurring practical issues are consistent across the region:

• CoPP validity windows — issued too early, it expires before filing completes.
• Commercial documents may need notarisation before qualifying for apostille.
• Certified Spanish translation meeting local formal requirements.
• Exact name consistency across CoPP, GMP certificate, manufacturing licence and power of attorney.

During the institutional transition, confirm where legalised documents should be submitted and in what form before dispatching originals.

Uruguay operates the same broad logic as the rest of the region: registration is the route to the market, and exceptional authorisations exist to cover genuine clinical need that the registered market cannot meet.

The circumstances in which unregistered product may be authorised are familiar:

• No registered equivalent suitable for the clinical requirement.
• Shortage or supply interruption threatening continuity of treatment.
• Public health need or declared emergency.
• Orphan and rare disease products where the Uruguayan market could never support a commercial registration — a real consideration in a country of roughly three and a half million people.
• Clinical trial material, under its own authorisation route tied to the approved protocol.

Two Uruguay-specific points matter more than the general rule.

Market size makes the exceptional route structurally more important here. For genuinely rare indications, the commercial case for a Uruguayan registration may never exist. Exceptional and named patient routes are not a workaround in those cases — they are the permanent and appropriate mechanism, and should be planned as such rather than treated as a stopgap.

The institutional transition adds a procedural question. With medicines regulation moving from the Ministry of Public Health to AViSU, confirm which body currently issues these authorisations and under what procedure before you rely on a timeline. Do not plan an urgent consignment on the basis of guidance that predates the new agency.

Authorisations are granted against a specific justification rather than as standing permission, and are normally applied for by the importing institution, licensed importer or treating physician rather than by the foreign manufacturer. Confirm current requirements before relying on any of this.

Named patient supply follows the regional principle: an unregistered medicine may be imported for an individually identified patient, on a treating physician's responsibility, where no suitable registered alternative exists.

Typically required:

• Prescription from a licensed physician naming the patient.
• Clinical justification for why no registered alternative is suitable.
• Authority authorisation obtained before the consignment moves.
• Quantity limited to the patient's treatment course.
• Batch Certificate of Analysis, provenance, and depending on the case a CoPP.

Compassionate use and expanded access — products still in clinical development, supplied outside a trial where no therapeutic alternative exists — sit under their own framework.

Uruguay is a more significant named patient market than its population suggests, for a specific reason. It is a high-income country with a well-organised health system and comparatively strong patient advocacy, which means unmet needs for rare-disease and high-cost therapies tend to be identified, articulated and pursued rather than going unaddressed. Requests are generally well-documented and clinically serious.

The operational demands are the regional norm — single packs, high urgency, documentation right first time. Uruguay adds one practical advantage: as a temperate market with reliable infrastructure, cold chain risk on the final leg is lower than in much of Latin America, though the international routing still requires proper qualification.

Further reading: our global guide to named patient import programmes, our named patient supply service, and our cold chain logistics page.

Uruguay's public procurement is comparatively organised and transparent, which is one of the reasons the market repays the effort despite modest volumes.

Institutional demand runs principally through the Ministry of Public Health and through ASSE (Administración de los Servicios de Salud del Estado), the state health services administration, with centralised purchasing arrangements used for significant volumes.

The distinctive Uruguayan feature is the Fondo Nacional de Recursos (FNR), the national resources fund, which finances high-cost procedures and high-cost medicines across the health system. For expensive specialty products — oncology, rare disease, biologics — the FNR rather than a hospital budget is frequently the body that determines whether a therapy is funded and on what terms.

This matters strategically. In most markets an exporter's commercial question is whether a hospital will buy. In Uruguay, for high-cost products, the prior question is whether the therapy is within the funded scope at all. A registration without funded status may produce very little volume, and understanding the funding pathway is as important as understanding the regulatory one.

A valid registration is generally required to bid, so the registration must be in place ahead of a tender rather than in response to one.

The PAHO Strategic Fund is available as a parallel route. It is the Pan American Health Organization's regional pooled-procurement mechanism for member states that have signed an agreement with the Organization, and eligibility rests on international qualification — criteria include WHO Prequalification status at the time of tender opening, and approval by regulatory authorities of regional reference — rather than separate national registration in each purchasing country. Confirm current criteria with PAHO.

Whichever route applies, the technical file decides the outcome before price is opened. Our government and institutional tender supply page sets out what it must contain.

The documentation burden scales with the route. Matching the right level to the right route saves both money and months — and in a market this size, choosing the wrong level can make an otherwise sound project uneconomic.

The Uruguayan conclusion runs against the regional pattern, and it is worth stating plainly. In larger markets, full registration is almost always the right long-term answer and the exceptional routes are a bridge to it. In Uruguay, for genuinely rare indications, the arithmetic can point the other way — the addressable patient population may never justify the cost of registration and its ongoing renewal and variation burden.

That is not a reason to avoid the market. It is a reason to decide, product by product, which route you are actually building for — and to be honest about it at the outset rather than registering on optimism and discovering the volume was never there.

Failure patterns specific to Uruguay, and to the current moment:

• Planning from outdated guidance. Material describing the pre-AViSU framework may no longer reflect the correct route or responsible office.
• Treating Uruguay as too small to structure properly — handing the registration to a distributor and losing control of a strategically useful Mercosur asset.
• Assuming a Mercosur filing transfers automatically. Harmonised technical standards reduce duplication; they do not create automatic recognition of another member's registration.
• Reusing tropical-zone stability data without confirming it is the appropriate evidence for a temperate market.
• Expired or mismatched supporting certificates, the most common avoidable cause of delay anywhere in Latin America.
• Relying on informal timeline assurances given during a period of institutional change.

Uruguay rewards a different kind of thinking from the rest of the region, so it is worth resisting the urge to run your standard playbook here.

Start by checking what is actually true this month. The MSP to AViSU handover means a good deal of published guidance — including advice you may get from people who know the market well — describes a system on its way out. Confirm the responsible body and the current filing route directly before you commit to a timeline or a budget. Get it in writing while things are moving.

Then be realistic about the timeline. New agencies are usually slower before they are faster, and query cycles cost more than usual while procedures are still bedding in. Plan for that instead of being annoyed by it.

If you already hold an ANMAT or ANVISA approval, lead with it. Both are PAHO reference authorities, both are Mercosur partners, and that is about as well-placed as leverage gets in this region.

Last, and this is the one people get wrong: decide per product whether you are actually building for registration at all. In most markets that question answers itself. In a country this size, for a genuinely rare indication, the patient numbers may never carry the cost of registering and then maintaining it. That is a legitimate answer — the named patient and exceptional routes exist precisely for those cases, and using them permanently is not a failure. Registering on optimism and discovering the volume was never there is the expensive version.

None of this is legal advice, and Uruguay in particular is a moving target right now. Confirm current requirements with the authority and take local advice before spending anything.